scispace - formally typeset
J

Jian Luo

Researcher at East China Normal University

Publications -  67
Citations -  3533

Jian Luo is an academic researcher from East China Normal University. The author has contributed to research in topics: Osteoclast & Metastasis. The author has an hindex of 31, co-authored 67 publications receiving 2952 citations. Previous affiliations of Jian Luo include Second Military Medical University & Hunan Normal University.

Papers
More filters
Journal ArticleDOI

ZNF411, a novel KRAB-containing zinc-finger protein, suppresses MAP kinase signaling pathway.

TL;DR: Results indicate that ZNF411 is a member of the zinc-finger transcription factor family and may be involved in the heart development, and it probably works as a negative regulator in MAPK signaling pathway.
Journal ArticleDOI

Inhibition of Osteoclastogenesis and Bone Resorption in vitro and in vivo by a prenylflavonoid xanthohumol from hops

TL;DR: It is demonstrated that xanthohumol inhibits osteoclastogenesis and bone resorption through RANK/TRAF6 signaling pathways and could be a promising drug candidate in the treatment of osteOClast-related diseases such as postmenopausal osteoporosis.
Journal ArticleDOI

Optimization of 2-(3-(arylalkyl amino carbonyl) phenyl)-3-(2-methoxyphenyl)-4-thiazolidinone derivatives as potent antitumor growth and metastasis agents.

TL;DR: Results suggested that the new series of 2-(3-(arylalkyl amino carbonyl)phenyl)-3-(2-methoxyphenyl)-4-thiazolidinone derivatives could be regarded and developed as novel highly potential anticancer agents in the future.
Journal ArticleDOI

Inhibition of transcriptional activities of AP-1 and c-Jun by a new zinc finger protein ZNF394.

TL;DR: Overexpression of ZNF394 in the cell inhibits the transcriptional activities of c-Jun and AP-1 reporters, suggesting that ZNF395 is a new transcriptional repressor in mitogen-activated protein kinase signaling pathways and may play an important role in cardiac development and/or cardiac function.
Journal ArticleDOI

Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.

TL;DR: It is demonstrated that plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment and that plumberagin may serve as a novel agent in the treatment of tumorBone metastasis.